Skip to main content

Milestone 6.F

Initiate phase ll (proof of concept) drug trials for agents against 3-6 novel therapeutic targets. These trials will provide proof of mechanism and/or evidence of target engagement of the target being tested.


Success Criteria

  • Completion of at least 6 phase II drug trials for agents against novel targets, providing conclusive evidence of therapeutic mechanism/target engagement.  Of these at least 3 trials should be in asymptomatic, at risk individuals (e.g. FAD or ApoE4 carriers, Down syndrome, amyloid positive, type II diabetes etc.)


Research Implementation Area
Drug Development - Novel Targets
Timeline
2020–2024
Status
In Progress

Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations